Stroke treatment developer Silk Road Medical (NSDQ:SILK) announced that it promoted Andrew Davis as its new chief commercial officer.
In the newly created role at the Sunnyvale, Calif.-based company, Davis is slated to oversee Silk Road Medical’s global commercialization efforts by establishing near-term priorities and setting the long-term strategic direction for the organization, according to a news release.
“Andy and his team have had a monumental role in our commercial success driving the safe adoption of [transcarotid artery revascularization] across the U.S.,” Silk Road Medical CEO Erica Rogers said in the release. “His contributions to the development of our sales team and commercial strategy have been vital to our organization. In his new role, we are confident that Andy will provide additional strategic direction and value and deliver meaningful and lasting results for Silk Road Medical.”
Davis joined the company as its first commercial leader in 2015 and constructed a sales team of over 100 customer-facing field members, helping to bring in over $125 million in cumulative revenue.
Before joining Silk Road Medical, Davis served as VP of advanced wound therapy sales and marketing in the U.S. and Canada at Acelity (which has since been acquired by 3M (NYSE:MMM)). Before that, he spent 15 years across numerous roles at Medtronic (NYSE:MDT).
“It is an exciting time to be at Silk Road as we continue to drive commercial execution in the U.S. and pursue market opportunities in new geographies and therapeutic areas,” Davis said. “I am looking forward to guiding these efforts as we increase our sales and marketing activities in our pursuit to change the standard of care.”